MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

87.88
+1.46
+1.69%
After Hours: 87.47 -0.41 -0.47% 16:10 10/21 EDT
OPEN
87.53
PREV CLOSE
86.42
HIGH
88.33
LOW
85.32
VOLUME
105.08K
TURNOVER
--
52 WEEK HIGH
219.61
52 WEEK LOW
82.31
MARKET CAP
1.36B
P/E (TTM)
-24.6397
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MDGL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MDGL News

  • Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
  • MotleyFool.com.5d ago
  • NGM Bio down 17% premarket on underwhelming data on NASH candidate
  • seekingalpha.10/07 18:16
  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 11:32
  • What Kind Of Share Price Volatility Should You Expect For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)?
  • Simply Wall St..09/19 20:28

More

Industry

Biotechnology & Medical Research
+1.34%
Pharmaceuticals & Medical Research
+0.39%

Hot Stocks

Name
Price
%Change

About MDGL

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
More

Webull offers Madrigal Pharmaceuticals Inc (MDGL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.